Press Release

Global Cancer Immunotherapy Drug Discovery Outsourcing Market to grow with a CAGR of 8.70 %

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Cancer Immunotherapy Drug Discovery Outsourcing Market.

 

According to TechSci Research report, “Global Cancer Immunotherapy Drug Discovery Outsourcing Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Cancer Immunotherapy Drug Discovery Outsourcing Market has valued at USD 1.05 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.70% through 2028. This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market. Advancements in immunotherapy in the context of cancer immunotherapy drug discovery outsourcing have been instrumental in revolutionizing cancer treatment. These advancements are characterized by innovative approaches, cutting-edge technologies, and a deeper understanding of the immune system's role in cancer. Immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, have shown remarkable success in treating various cancers. These drugs block the inhibitory signals that cancer cells use to evade the immune system. Outsourcing firms have been deeply involved in the development and testing of these therapies. Chimeric Antigen Receptor T-cell (CAR-T) therapies involve engineering a patient's T-cells to target specific cancer antigens. These therapies have achieved remarkable results in treating hematological malignancies, and research is ongoing to expand their applicability to solid tumors. Bispecific antibodies are designed to simultaneously target cancer cells and immune cells. They enhance the immune system's ability to recognize and destroy cancer cells, and outsourcing firms have played a role in their development.

 

Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " Global Cancer Immunotherapy Drug Discovery Outsourcing Market.”

 

In February 2023, Personalis, Inc., a prominent player in advanced genomics for precision oncology, has announced a new agreement with Moderna, Inc., a pioneering biotechnology company in the field of messenger RNA (mRNA) therapeutics and vaccines. This agreement extends the use of the Personalis NeXT Platform in upcoming clinical studies focused on mRNA-4157/V940, an investigational personalized cancer vaccine jointly developed by Moderna and Merck (known as MSD outside of the United States and Canada). The NeXT Platform, previously employed in the Phase 2b clinical study of the vaccine candidate, will continue to be utilized. It serves the purpose of sequencing genomic data derived from a patient's tumor sample. This sequencing is aimed at identifying the distinct genetic mutations that are most likely to elicit a customized antitumor response. Personalis, Inc. is at the forefront of advanced cancer genomics, facilitating the development of the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform is thoughtfully designed to adapt to the intricate and ever-evolving landscape of cancer. It equips biopharmaceutical clients and healthcare practitioners with comprehensive information on all approximately 20,000 human genes and the immune system, all derived from a single sample. Adverse events and safety concerns are a significant challenge in the Global Cancer Immunotherapy Drug Discovery Outsourcing Market. Cancer immunotherapies work by modulating the patient's immune system. However, this complex interaction can lead to unintended immune-related adverse events (irAEs). Identifying and managing these events is a challenge. Immunotherapies can produce unpredictable responses in patients. Some individuals may experience significant side effects, while others may respond well to the treatment. Predicting and managing these varying responses is a challenge. Some irAEs may have a delayed onset, appearing weeks or even months after treatment initiation. Monitoring and managing these late-onset events require long-term follow-up and data analysis. Immunotherapies can sometimes lead to autoimmune reactions where the immune system attacks healthy tissues. Identifying and managing such reactions is crucial for patient safety. Biomarkers for predicting and monitoring irAEs are not always well-established. Developing reliable biomarkers to assess patient safety is an ongoing challenge. The heterogeneity of patient populations means that safety concerns can vary. Patients with different genetic backgrounds and health conditions may have different safety profiles.

Global Cancer Immunotherapy Drug Discovery Outsourcing Market is segmented based on Drug Type, Service Type, Cancer Type, and by region. Based on the Drug Type, Global Cancer Immunotherapy Drug Discovery Outsourcing Market is segmented into Monoclonal Antibodies, Immunomodulators, Cancer Vaccines and Oncolytic Viral Therapy, others. Oncolytic Viral Therapy is an innovative approach within the field of cancer immunotherapy that involves using specially engineered viruses to target and destroy cancer cells. When applied in the context of Immunotherapy Drug Discovery Outsourcing, it means utilizing external expertise, resources, and contract research organizations (CROs) to research, develop, and advance oncolytic viral therapies for cancer treatment. Oncolytic viral therapy involves using viruses that are modified to selectively infect and replicate within cancer cells while leaving normal, healthy cells unharmed. These modified viruses can directly lyse (destroy) cancer cells, releasing antigens and signals that stimulate the patient's immune system to recognize and attack the cancer.

Based on Region, North America held the largest share in the Global Cancer Immunotherapy Drug Discovery Outsourcing Market. The North American region has seen significant collaborations between pharmaceutical companies, research institutions, and outsourcing service providers. These partnerships drive innovation and accelerate the drug discovery process. North America is known for its extensive clinical trial infrastructure, making it a prime location for testing new cancer immunotherapies. This infrastructure is essential for advancing drug development. The region's diverse population provides a broad patient pool for clinical trials. This diversity can be valuable in understanding the effectiveness of immunotherapies across different demographic groups. There is a high demand for cancer immunotherapy services in North America due to the prevalence of cancer and the willingness of patients to explore innovative treatment options. North American companies often collaborate with international partners and clients, extending their reach in the global market.

 

Some of the major companies operating in the Global Cancer Immunotherapy Drug Discovery Outsourcing Market include:

  • Covance, Inc.
  • Horizon Discovery Group PLC
  • Crown Bioscience, Inc.
  • Promega Corporation
  • HD Biosciences Co., Ltd.
  • BPS Bioscience, Inc.
  • Genscript Biotech Corporation
  • DiscoverX Corporation
  • Celentyx Ltd.
  • ImmunXperts SA


Download Free Sample Report

Customers can also request for 10% free customization on this report.

“Certain areas, particularly in North America, are projected to exert significant demand for Cancer Immunotherapy Drug Discovery Outsourcing. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Cancer Immunotherapy Drug Discovery Outsourcing Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

Cancer Immunotherapy Drug Discovery Outsourcing Market by Drug Type (Monoclonal Antibodies, Immunomodulators, Cancer Vaccines and Oncolytic Viral Therapy, others), By Service Type (Target Identification and Validation, Lead Screening and Characterization, Cell-based Assays), by Cancer Type (Lung, Breast, Colorectal, Melanoma, Prostate, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F has evaluated the future growth potential of Global Cancer Immunotherapy Drug Discovery Outsourcing Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Cancer Immunotherapy Drug Discovery Outsourcing Market.


 

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]               

Website: www.techsciresearch.com

Relevant News